CLIN.L Share News (CLIN)

CLIN.L Information

There is currently no data for CLIN

Clinigen signs UK distribution deal for Paion hospital drugs

Thu, 02nd Sep 2021 14:28

(Alliance News) - Clinigen Group PLC on Thursday said it has signed an exclusive deal to distribute in the UK drugs developed by Paion AG.

Aachen, Germany-based Paion develops drugs used for hospital-based sedation, anesthesia and critical care. Clinigen is based in Burton-upon-Trent and signs partnerships with drug developers to help launch and distribute their products.

Paion's Byfavo drug, a sedative given to patients undergoing invasive medical procedures, was approved in the UK this year. It has two more products recently launched outside the UK - Giapreza, an injection to increase blood pressure, and Xerava, for treating complicated intra-abdominal infections.

Under the terms of the deal, Clinigen will supply and distribute Paion's licensed products in the UK.

"We are pleased to be partnering with Paion for their first commercial launch in the UK and to be able to offer Byfavo to healthcare providers across the UK through our lifecycle platform," Clinigen Chief Operating Officer Sam Herbert said.

Shares in Clinigen were up 0.4% to 617.50 pence in London. Paion was up 1.2% to EUR1.88 in Frankfurt.

By Ivan Edwards; ivanedwards@alliancenews.com

More News

14 Jul 2020 09:07

Clinigen FY revenues continue to rise, profit growth slowed by Covid-19

(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pandemic and the launch of a low-cost competitor to its Foscavir drug.

13 Jul 2020 16:29

Clinigen gets orphan drug designation for 'aldesleukin' in the US

(Sharecast News) - Pharmaceutical services company Clinigen Group announced on Monday that the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted orphan drug designation for 'aldesleukin', in the treatment of amyotrophic lateral sclerosis (ALS).

13 Jul 2020 13:48

Monday broker round-up

(Sharecast News) - Kingfisher: RBC Capital Markets reiterates outperform with a target price of 275.0p

13 Jul 2020 08:41

Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin

14 Jun 2020 19:22

Sunday newspaper round-up: Two meters, Rolls Royce, Clinigen

(Sharecast News) - Senior scientists have reported flaws in an influential World Health Organization-commissioned study into the risks of coronavirus infection and say it should not be used as evidence for relaxing the UK's 2-metre physical distancing rule. Critics of the distancing advice, which states that people should keep at least 2 metres apart, believe it is too cautious. They seized on the research commissioned by the WHO, which suggested a reduction from 2 metres to 1 would raise infection risk only marginally, from 1.3% to 2.6%. - Guardian

28 May 2020 13:34